Annie M. Guerin

1 Ibragimov St
Almaty, ALA 050032, Kazakhstan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Journal: Leukemia & lymphoma
Published: July 29, 2026

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.

Journal: Dermatology and therapy
Published: April 14, 2026

First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States.

First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States.

Journal: Breast cancer research and treatment
Published: February 24, 2026

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Journal: The oncologist
Published: February 18, 2026

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.

Journal: Dermatology and therapy
Published: January 27, 2026

Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomnia.

Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomnia.

Journal: Sleep medicine
Published: January 15, 2026

Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.

Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.

Journal: Clinical lung cancer
Published: January 07, 2026

Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.

Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.

Journal: Neurology and therapy
Published: December 16, 2025

Early real-world utilization of ADA-adaz (Hyrimoz) in the United States: A retrospective claims-based descriptive study.

Early real-world utilization of ADA-adaz (Hyrimoz) in the United States: A retrospective claims-based descriptive study.

Journal: Medicine
Published: November 07, 2025

Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis.

Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis.

Journal: Medicine
Published: November 05, 2025

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.

Journal: Cancer medicine
Published: September 19, 2025

Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy.

Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy.

Journal: Hepatology communications
Published: July 10, 2025
Showing 1-12 of 183

Last Updated: 09/26/2026